INTS vs NEM · $7.7M cap vs P/E 14, rev $22.67B
Intensity Therapeutics, Inc. Common stock (INTS) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
INTS does not have a complete income-statement cache yet.
Latest reported NEM revenue for 2025-12-31 was $22.67B. Net income was $7.08B. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
INTS currently screens at market cap $7.7M. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the INTS and NEM stock pages for the full models.
Not investment advice.